Understanding Sociodemographic Factors among Hispanics Through a Population-Based Study on Testicular Cancer in Mexico.

Cancer survival Health disparities Hispanic population Incidence trends TGCT Testicular cancer

Journal

Journal of racial and ethnic health disparities
ISSN: 2196-8837
Titre abrégé: J Racial Ethn Health Disparities
Pays: Switzerland
ID NLM: 101628476

Informations de publication

Date de publication:
14 Nov 2023
Historique:
received: 29 09 2023
accepted: 27 10 2023
revised: 26 10 2023
medline: 14 11 2023
pubmed: 14 11 2023
entrez: 14 11 2023
Statut: aheadofprint

Résumé

Testicular cancer (TCa) is a rare malignancy affecting young men worldwide. Sociodemographic factors, especially socioeconomic level (SEL) and healthcare access, seem to impact TCa incidence and outcomes, particularly among Hispanic populations. However, limited research has explored these variables in Hispanic groups. This study aimed to investigate sociodemographic and clinical factors in Mexico and their role in health disparities among Hispanic TCa patients. We retrospectively analyzed 244 Mexican TCa cases between 2007 and 2020 of a representative cohort with diverse social backgrounds from a national reference cancer center. Logistic regression identified risk factors for fatality: non-seminoma histology, advanced stage, and lower education levels. Age showed a significant trend as a risk factor. Patient delay and healthcare distance lacked significant associations. Inadequate treatment response and chemotherapy resistance were more likely in advanced stages, while higher education positively impacted treatment response. Cox regression highlighted non-seminoma histology, below-median SEL, higher education, and advanced-stage survival rates. Survival disparities emerged based on tumor histology and patient SEL. This research underscores the importance of comprehensive approaches that integrate sociodemographic, biological, and environmental factors to address health disparities improving outcomes through personalized interventions in Hispanic individuals with TCa.

Identifiants

pubmed: 37962789
doi: 10.1007/s40615-023-01859-0
pii: 10.1007/s40615-023-01859-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Health Mexico
ID : FPIS-INCAN-4352

Informations de copyright

© 2023. The Author(s).

Références

Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/CAAC.21660 .
doi: 10.3322/CAAC.21660 pubmed: 33538338
Znaor A, et al. Testicular cancer incidence predictions in Europe 2010–2035: a rising burden despite population ageing. Int J Cancer. 2020;147(3):820–8. https://doi.org/10.1002/IJC.32810 .
doi: 10.1002/IJC.32810 pubmed: 31773729
Gurney JK, et al. International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries. Eur Urol. 2019;76(5):615–23. https://doi.org/10.1016/J.EURURO.2019.07.002 .
doi: 10.1016/J.EURURO.2019.07.002 pubmed: 31324498 pmcid: 8653517
Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol. 2014;65(6):1095–106. https://doi.org/10.1016/J.EURURO.2013.11.004 .
doi: 10.1016/J.EURURO.2013.11.004 pubmed: 24268506
Ghazarian AA, McGlynn KA. Increasing incidence of testicular germ cell tumors among racial/ethnic minorities in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(6):1237–45. https://doi.org/10.1158/1055-9965.EPI-20-0107 .
doi: 10.1158/1055-9965.EPI-20-0107 pubmed: 32385118 pmcid: 7269801
Ghazarian AA, Kelly SP, Altekruse SF, Rosenberg PS, McGlynn KA. Future of testicular germ cell tumor incidence in the United States: forecast through 2026. Cancer. 2017;123(12):2320–8. https://doi.org/10.1002/CNCR.30597 .
doi: 10.1002/CNCR.30597 pubmed: 28241106
Sohail M, et al. Mexican Biobank advances population and medical genomics of diverse ancestries. Nature. 2023;622(7984):775–83. https://doi.org/10.1038/s41586-023-06560-0 .
doi: 10.1038/s41586-023-06560-0 pubmed: 37821706 pmcid: 10600006
DeRouen MC, et al. Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California. Cancer Causes Control. 2020;31(8):713–21. https://doi.org/10.1007/s10552-020-01311-2 .
doi: 10.1007/s10552-020-01311-2 pubmed: 32440828
Lerro CC, Robbins AS, Fedewa SA, Ward EM. Disparities in stage at diagnosis among adults with testicular germ cell tumors in the National Cancer Data Base. Urol Oncol: Semin Original Inv. 2014;32(1):23.e15-23.e21. https://doi.org/10.1016/j.urolonc.2012.08.012 .
doi: 10.1016/j.urolonc.2012.08.012
Znaor A, et al. Global patterns in testicular cancer incidence and mortality in 2020. Int J Cancer. 2022;151(5):692–8. https://doi.org/10.1002/IJC.33999 .
doi: 10.1002/IJC.33999 pubmed: 35277970
Pishgar F, et al. Global, regional and national burden of testicular cancer, 1990–2016: results from the Global Burden of Disease Study 2016. BJU Int. 2019;124(3):386–94. https://doi.org/10.1111/BJU.14771 .
doi: 10.1111/BJU.14771 pubmed: 30953597
Taylor ZD, McLeod E, Gard CC, Woods ME. Testicular cancer incidence and mortality in New Mexico. Ethn Dis. 2020;30(2):357–64. https://doi.org/10.18865/ed.30.2.357 .
doi: 10.18865/ed.30.2.357 pubmed: 32346282 pmcid: 7186055
Chien FL, Schwartz SM, Johnson RH. Increase in testicular germ cell tumor incidence among Hispanic adolescents and young adults in the United States. Cancer. 2014;120(17):2728–34. https://doi.org/10.1002/cncr.28684 .
doi: 10.1002/cncr.28684 pubmed: 25044313
Ferlay J, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–89. https://doi.org/10.1002/IJC.33588 .
doi: 10.1002/IJC.33588
Gurrola-Ortega Á, et al. Cáncer testicular: incidencia, epidemiología y etiología. Cinco años de experiencia en el Hospital General de México Dr. Eduardo Liceaga. Rev Mex Urol. 2018;78(5):347–53. https://doi.org/10.24245/REVMEXUROL.V78I5.2408 .
doi: 10.24245/REVMEXUROL.V78I5.2408
Bourlon MT, Ceja-Bojorge AC, Noguez-Ramos A, Cordova-Ramos JC, Melendez FDH, Rodriguez EL. Testicular cancer in Mexico: clinicopathologic and prognostic study with analysis of causes of death and palliative requirements. J Clin Oncol. 2014;32(15_suppl). https://doi.org/10.1200/jco.2014.32.15_suppl.e20550
Costilla-Montero A, et al. Cáncer testicular. Experiencia en el Centro Médico del Instituto de Seguridad Social del Estado de México y Municipios (ISSEMyM). Rev Mex Urol. 2011;71(6):307–313. Accessed: Sep. 24, 2023. [Online]. Available: https://www.elsevier.es/es-revista-revista-mexicana-urologia-302-articulo-cancer-testicular-experiencia-el-centro-X2007408511938719 .
Mx S, et al. “Epidemiología descriptiva de cáncer en el Instituto Nacional de Cancerología de México,” Salud Publica Mex. 1997;39(4):0-undefined. Accessed: Sep. 25, 2023. [Online]. Available: https://www.redalyc.org/articulo.oa?id=10639402 .
Jiménez-Ríos MÁ, et al. “Panorama epidemiológico del cáncer genitourinario en la Zona Centro de México. Rev Mex Urol. 2011;71:3–6. Accessed: Sep. 25, 2023. [Online]. Available: https://www.elsevier.es/es-revista-revista-mexicana-urologia-302-articulo-panorama-epidemiologico-del-cancer-genitourinario-X2007408511358489 .
Ghazarian AA, Trabert B, Devesa SS, McGlynn KA. Recent trends in the incidence of testicular germ cell tumors in the United States. Andrology. 2015;3(1):13–8. https://doi.org/10.1111/andr.288 .
doi: 10.1111/andr.288 pubmed: 25331158
Silva Arciniega MR, Brain Calderón ML. Validez y Confiabilidad del Estudio Socioeconómico. 2nd ed. Universidad Nacional Autónoma de México, Escuela Nacional de Trabajo Social; 2016.
Richardson LC, Neri AJ, Tai E, Glenn JD. Testicular cancer: a narrative review of the role of socioeconomic position from risk to survivorship. Urol Oncol. 2012;30(1):95. https://doi.org/10.1016/J.UROLONC.2011.09.010 .
doi: 10.1016/J.UROLONC.2011.09.010 pubmed: 22127018
Johnson TV, Hsiao W, Jani A, Master VA. Increased mortality among Hispanic testis cancer patients independent of neighborhood socioeconomic status: a SEER study. J Immigr Minor Health. 2011;13(5):818–24. https://doi.org/10.1007/S10903-010-9419-4/METRICS .
doi: 10.1007/S10903-010-9419-4/METRICS pubmed: 21140218
Li Y, Lu Q, Wang Y, Ma S. Racial differences in testicular cancer in the United States: descriptive epidemiology. BMC Cancer. 2020;20(1):1–10. https://doi.org/10.1186/S12885-020-06789-2/TABLES/3 .
doi: 10.1186/S12885-020-06789-2/TABLES/3
Woldu SL, Amatruda JF, Bagrodia A. Testicular germ cell tumor genomics. Curr Opin Urol. 2017;27(1):41–7. https://doi.org/10.1097/MOU.0000000000000347 .
doi: 10.1097/MOU.0000000000000347 pubmed: 27584029 pmcid: 6368344
Demant P. The genetic factors in cancer development and their implications for cancer prevention and detection. Radiat Res. 2005;164(4 Pt 2):462–6. https://doi.org/10.1667/RR3333.1 .
doi: 10.1667/RR3333.1 pubmed: 16187750
Yazici S, et al. Risk factors for testicular cancer: environment, genes and infections—is it all? Medicina. 2023;59(4):724. https://doi.org/10.3390/MEDICINA59040724 .
doi: 10.3390/MEDICINA59040724 pubmed: 37109682 pmcid: 10145700
González-Barrios R, et al. Genomic profile in a non-seminoma testicular germ-cell tumor cohort reveals a potential biomarker of sensitivity to platinum-based therapy. Cancers (Basel). 2022;14(9):2065. https://doi.org/10.3390/cancers14092065 .
doi: 10.3390/cancers14092065 pubmed: 35565196
Williams LA, Frazier AL, Poynter JN. Survival differences by race/ethnicity among children and adolescents diagnosed with germ cell tumors. Int J Cancer. 2020;146(9):2433–41. https://doi.org/10.1002/ijc.32569 .
doi: 10.1002/ijc.32569 pubmed: 31304572
Fosså SD, et al. Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol. 2011;29(8):963–70. https://doi.org/10.1200/JCO.2010.32.3204 .
doi: 10.1200/JCO.2010.32.3204 pubmed: 21300926
Derouen MC, Mujahid M, Srinivas S, Keegan THM. Disparities in adolescent and young adult survival after testicular cancer vary by histologic subtype: a population-based study in California 1988–2010. J Adolesc Young Adult Oncol. 2016;5(1):31–40. https://doi.org/10.1089/JAYAO.2015.0041 .
doi: 10.1089/JAYAO.2015.0041 pubmed: 26812451 pmcid: 4779289
DeRouen MC, Mujahid M, Srinivas S, Keegan THM. Disparities in adolescent and young adult survival after testicular cancer vary by histologic Subtype: A Population-Based Study in California 1988–2010. J Adolesc Young Adult Oncol. 2016;5:31–40. https://doi.org/10.1089/jayao.2015.0041 .
Kharazmi E, et al. Cancer risk in relatives of testicular cancer patients by histology type and age at diagnosis: a joint study from five Nordic countries. Eur Urol. 2015;68(2):283–9. https://doi.org/10.1016/J.EURURO.2014.12.031 .
doi: 10.1016/J.EURURO.2014.12.031 pubmed: 25913387
Parada H, Vu AH, Pinheiro PS, Thompson CA. Comparing age at cancer diagnosis between Hispanics and Non-Hispanic Whites in the United States. Cancer Epidemiol Biomarkers Prev. 2021;30(10):1904–12. https://doi.org/10.1158/1055-9965.EPI-21-0389 .
doi: 10.1158/1055-9965.EPI-21-0389 pubmed: 34321282 pmcid: 8492520
Gleason AM. Racial disparities in testicular cancer: impact on health promotion. J Transcult Nurs. 2006;17(1):58–64. https://doi.org/10.1177/1043659605281980 .
doi: 10.1177/1043659605281980 pubmed: 16410437
Fonseca A, Lindsay Frazier A, Shaikh F. Germ cell tumors in adolescents and young adults. J Oncol Pract. 2019;15(8):433–41. https://doi.org/10.1200/JOP.19.00190 .
doi: 10.1200/JOP.19.00190 pubmed: 31404512
Wynd CA. Testicular self-examination in young adult men. J Nurs Scholarsh. 2002;34(3):251–5. https://doi.org/10.1111/J.1547-5069.2002.00251.X .
doi: 10.1111/J.1547-5069.2002.00251.X pubmed: 12237987
Gascoigne P, Whitear B. Making sense of testicular cancer symptoms: a qualitative study of the way in which men sought help from the health-care services. Eur J Oncol Nurs. 1999;3(2):62–9. https://doi.org/10.1016/S1462-3889(99)81296-4 .
doi: 10.1016/S1462-3889(99)81296-4
Brodsky MS. The young male experience with treatment for nonseminomatous testicular cancer. Sex Disabil. 1999;17(1):65–77. https://doi.org/10.1023/A:1021455813897/METRICS .
doi: 10.1023/A:1021455813897/METRICS
Nakagawa T, et al. Fructose contributes to the Warburg effect for cancer growth. Cancer Metab. 2020;8(1):1–12. https://doi.org/10.1186/S40170-020-00222-9 .
doi: 10.1186/S40170-020-00222-9
Webster BR, Riley JM, Davis MS. Initial presentation and outcomes of testicular cancer among different racial and ethnic groups at a tertiary care facility in New Mexico. Urol Pract. 2021;8(1):71–7. https://doi.org/10.1097/UPJ.0000000000000153 .
doi: 10.1097/UPJ.0000000000000153 pubmed: 37145426
Macleod LC, et al. Disparities in access and regionalization of care in testicular cancer. Clin Genitourin Cancer. 2018;16(4):e785–93. https://doi.org/10.1016/J.CLGC.2018.02.014 .
doi: 10.1016/J.CLGC.2018.02.014 pubmed: 29605587
Chertack N, et al. Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. Cancer. 2020;126(19):4362–70. https://doi.org/10.1002/CNCR.33076 .
doi: 10.1002/CNCR.33076 pubmed: 32776520
Palumbo C, et al. Contemporary incidence and mortality rates in patients with testicular germ cell tumors. Clin Genitourin Cancer. 2019;17(5):e1026–35. https://doi.org/10.1016/j.clgc.2019.06.003 .
doi: 10.1016/j.clgc.2019.06.003 pubmed: 31378580
Di Domenico D, Bridges P, Sharifi R, Rubenstein M, Guinan P. Survival of Mexican-American males with seminoma. Rev Invest Clin. 1997;49(2):93–96. Accessed Sep 24 2023. [Online]. Available: https://europepmc.org/article/MED/9294957 .
Woldu SL, Bagrodia A. Update on epidemiologic considerations and treatment trends in testicular cancer. Curr Opin Urol. 2018;28(5):440–7. https://doi.org/10.1097/MOU.0000000000000532 .
doi: 10.1097/MOU.0000000000000532 pubmed: 30004908 pmcid: 6134403
Mitric C, Bernardini MQ. Endometrial cancer: transitioning from histology to genomics. Curr Oncol. 2022;29(2):741–57. https://doi.org/10.3390/curroncol29020063 .
doi: 10.3390/curroncol29020063 pubmed: 35200562 pmcid: 8870297
Murumägi A, et al. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma. Br J Cancer. 2022;128(4):678–90. https://doi.org/10.1038/s41416-022-02067-z .
doi: 10.1038/s41416-022-02067-z pubmed: 36476658 pmcid: 9938120
Medvedev KE, Savelyeva AV, Chen KS, Bagrodia A, Jia L, Grishin NV. Integrated Molecular Analysis Reveals 2 Distinct Subtypes of Pure Seminoma of the Testis. Cancer Inform. 2022;21:1–10. https://doi.org/10.1177/11769351221132634
Li H, et al. Urological second malignant neoplasms in testicular nonseminoma survivors: a population-based analysis. Int Urol Nephrol. 2021;53(3):471–7. https://doi.org/10.1007/S11255-020-02659-9 .
doi: 10.1007/S11255-020-02659-9 pubmed: 33052518
Aguilar-Ponce J, Chilaca Rosas F, Molina Calzada C, Granados García M, Jiménez Ríos MÁ, De La Garza Salazar J. Testicular cancer in androgen insensitivity syndrome in a Mexican population. Clin Transl Oncol. 2008;10(12):840–3. https://doi.org/10.1007/S12094-008-0298-2/METRICS .
doi: 10.1007/S12094-008-0298-2/METRICS pubmed: 19068456
Gómez-Villanueva Á, Sánchez JC, Arreygue LS, González YS, del Socorro Romero-Figueroa M. Incidencia de cáncer en una Unidad de Atención Oncológica del Instituto Mexicano del Seguro Social (IMSS), en Toluca, Estado de México. Gac Med Mex. 2014;150:297–303.
pubmed: 25098214
Cuevas-Estrada B, Montalvo-Casimiro M, Munguia-Garza P, Ríos-Rodríguez JA, González-Barrios R, Herrera LA. Breaking the mold: epigenetics and genomics approaches addressing novel treatments and chemoresponse in TGCT patients. Int J Mol Sci. 2023;24(9):7873. https://doi.org/10.3390/IJMS24097873 .
doi: 10.3390/IJMS24097873 pubmed: 37175579 pmcid: 10178517
Ghazarian AA, Trabert B, Graubard BI, Schwartz SM, Altekruse SF, McGlynn KA. Incidence of testicular germ cell tumors among US men by census region. Cancer. 2015;121(23):4181–9. https://doi.org/10.1002/CNCR.29643 .
doi: 10.1002/CNCR.29643 pubmed: 26280359
Scavuzzo A, Figueroa-Rodriguez P, Stefano A, Jimenez Guedulain N, Muruato Araiza S, Cendejas Gomez JdJ, Quiroz Compeaán A, Victorio Vargas DO, Jiménez-Ríos MA. CT rendering and radiomic analysis in post-chemotherapy retroperitoneal lymph node dissection for testicular cancer to anticipate difficulties for young surgeons. J Imaging. 2023;9(3):71. https://doi.org/10.3390/jimaging9030071 .

Auteurs

Juan Alberto Ríos-Rodríguez (JA)

Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, 14080, México.
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de La Salud, Monterrey, 64710, México.

Michel Montalvo-Casimiro (M)

Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, 14080, México.

Diego Ivar Álvarez-López (DI)

Unidad de Epidemiología en Cáncer, Instituto Nacional de Cancerología, Mexico City, 14080, México.

Nancy Reynoso-Noverón (N)

Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, 14080, México.
Unidad de Epidemiología en Cáncer, Instituto Nacional de Cancerología, Mexico City, 14080, México.

Berenice Cuevas-Estrada (B)

Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, 14080, México.

Julia Mendoza-Pérez (J)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Miguel A Jiménez-Ríos (MA)

Departamento de Urología, Instituto Nacional de Cancerología, Mexico City, 14080, México.

Talia Wegman-Ostrosky (T)

Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, 14080, México.

Pamela Salcedo-Tello (P)

Departamento de Bioquímica, Facultad de Medicina, UNAM, Mexico City, 04510, México.

Anna Scavuzzo (A)

Departamento de Urología, Instituto Nacional de Cancerología, Mexico City, 14080, México.

Clementina Castro-Hernández (C)

Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, 14080, México.

Luis A Herrera (LA)

Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, 14080, México. herream@biomedicas.unam.mx.
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de La Salud, Monterrey, 64710, México. herream@biomedicas.unam.mx.

Rodrigo González-Barrios (R)

Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Mexico City, 14080, México. rodrigop@ciencias.unam.mx.
Departamento de Biología Celular, Facultad de Ciencias, UNAM, Mexico City, 04510, México. rodrigop@ciencias.unam.mx.

Classifications MeSH